Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Arbutus Biopharma (ABUS) has demonstrated significant outperformance year-to-date, posting a 37.3% return against the Medical sector's average gain of 2.5% and its Biomedical and Genetics industry's 8.8%. This strong performance is supported by a Zacks Rank #2 (Buy) and a 15.6% increase in its full-year earnings consensus estimate over the past quarter. Similarly, Boston Scientific (BSX) also shows solid outperformance within the Medical sector, returning 7.7% year-to-date, with a Zacks Rank #2 (Buy) and a 2.1% rise in its current year EPS estimate.

Analysis

Arbutus Biopharma (ABUS) has demonstrated significant market outperformance, with its year-to-date return of 37.3% substantially exceeding the Medical sector's average gain of 2.5% and its direct industry group's (Medical - Biomedical and Genetics) return of 8.8%. This price momentum is supported by strengthening fundamentals, as indicated by a 15.6% upward revision in the Zacks Consensus Estimate for its full-year earnings over the last quarter. This positive shift in analyst sentiment is the primary driver behind its current Zacks Rank of #2 (Buy), which suggests a favorable outlook for the next one to three months. For context, Boston Scientific (BSX) is also highlighted as an outperformer, though more modestly, with a 7.7% year-to-date return and a 2.1% increase in its consensus EPS estimate. Both companies operate within the favorably ranked Medical sector (Zacks Sector Rank #3), but ABUS's performance and earnings estimate revision velocity are markedly superior to both its peer BSX and its respective industry averages.

Key Decisions for Investors

• Given Arbutus Biopharma's strong price momentum and the significant 15.6% upward revision in earnings estimates, investors with a higher risk tolerance might consider it a candidate for continued outperformance, contingent on the positive analyst sentiment holding.
• Investors should closely monitor future earnings estimate revisions for both ABUS and BSX, as the Zacks Rank model heavily weights this factor, and any deceleration or reversal could be a leading indicator of a trend change.
• For those seeking exposure to the outperforming Medical sector but with a potentially more stable profile, Boston Scientific represents a less volatile alternative to Arbutus, offering positive returns and earnings outlook but with less dramatic price movement.
• The data suggests a strategy of identifying top performers within favorably ranked sectors; therefore, investors should assess whether ABUS's 37.3% run-up still offers upside or if capital might be better allocated to other names in the #3 ranked Medical sector that have not yet experienced such a sharp appreciation.